No Single Radiotracer Tells the Whole Story: A Multitracer PET/CT Case in Medullary Thyroid Carcinoma (EANM 2026) - Sep 29, 2026 - Abstract #EP-1440; "Materials and A 59-year-old male with metastatic medullary thyroid carcinoma (MTC), previously treated with 177Lu-DOTATATE, stereotactic body radiation therapy (SBRT), vandetanib, and cabozantinib, was referred to our department for evaluation of molecular imaging and radioligand therapy (RLT) following biochemical progression, indicated by rising calcitonin and carcinoembryonic antigen (CEA) levels during treatment... This case illustrates how a single PET radiotracer can overlook clinically significant disease in metastatic medullary thyroid cancer (MTC). By integrating SSTR, 18F-DOPA, 18F-FDG, and 68Ga-FAPI PET/CT, we uncovered significant lesion-level heterogeneity and identified FAPI-targeted therapy as the most pertinent next theranostic option. For selected, heavily pretreated MTC patients, a customized multitracer approach may offer a more comprehensive understanding of disease biology and facilitate more personalized treatment decisions."
Clinical • Hepatology • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • CEACAM5 • SSTR
|